ARCT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Arcturus Therapeutics Holdings Inc (ARCT) is not a strong buy for a beginner, long-term investor at this time. While the stock appears undervalued based on analyst commentary and trades near its cash position, the lack of recent positive catalysts, weak financial performance, and negative short-term stock trend make it a less compelling investment currently. A hold position is recommended until further clarity on its financials or clinical progress emerges.
The MACD is positive and expanding, indicating bullish momentum. However, the RSI is neutral at 75.694, and moving averages are converging, suggesting no strong trend. The stock is trading near its resistance level (R1: 8.425), which could limit upward movement in the short term.
Roth Capital initiated a Buy rating with a $20 price target, citing the stock's mispricing and potential for over $1B in peak sales. The stock trades near its cash position, implying significant upside potential if clinical programs succeed.
Citi lowered the price target to $7, reflecting cautious sentiment. Financial performance in Q3 2025 showed a significant revenue decline (-58.84% YoY), and the stock is projected to decline in the short term (-4.34% in the next week). No recent news or congress trading data to support a positive momentum.
In Q3 2025, revenue dropped by 58.84% YoY to $17.15M. However, net income improved to -$13.45M (up 94.81% YoY), and EPS increased to -0.49 (up 88.46% YoY). Gross margin remained stable at 100%. Despite some improvement in profitability metrics, the revenue decline is concerning.
Roth Capital initiated a Buy rating with a $20 price target, highlighting the stock's undervaluation and clinical potential. Citi, however, lowered its price target to $7 and maintained a Neutral rating, reflecting mixed sentiment among analysts.
